Baekeland Fonds Home Baekeland Fonds I Baekeland Fonds II English Nederlands
ActoGeniX closes EUR 10.7 million financing round PDF

18/04/2013 - ActoGeniX, a clinical stage biopharmaceutical company, successfully closed a Series B equity financing round, raising EUR 10.7 million (USD 14 million). This financing round was led by new investor Saffelberg Investments (Belgium). ActoGeniX's founders and current investors all participated in this transaction, thus confirming their commitment to the strategic roadmap.

This financing round will allow ActoGeniX to execute its business strategy and fund ongoing and planned development programs.

ActoGeniX focuses on the development and commercialization of ActoBiotics, a novel class of orally administered and locally acting biopharmaceuticals. ActoBiotics represent a novel concept for oral administration of therapeutic proteins, and are designed to be safer and more effective than injectable biopharmaceuticals.

ActoGeniX is developing ActoBiotics in mucosal and immune diseases such as oral mucositis, inflammatory bowel disease, celiac disease, and type 1 diabetes.

Dr. Bernard Coulie, CEO of ActoGeniX, comments: "We are delighted with this financing, accomplished in a challenging market environment. It provides ActoGeniX with sufficient funding to execute its ambitious business plan. It will enable us to progress our pipeline including bringing key products to clinical proof of concept."

Dr. Staf Van Reet, Chairman of the Board of ActoGeniX, adds: "To have raised such a substantial amount of new equity capital during these times is a clear vote of confidence in ActoGeniX┬┤s promising platform and pipeline. It provides ActoGeniX with a far stronger position when presenting its platform and pipeline to potential pharma partners."